Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2025-08-05 03:49Core Viewpoint - Novo Nordisk (NVO.US) is facing a shareholder lawsuit due to a downward revision of its full-year revenue and operating profit growth expectations, citing challenges in the GLP-1 market as the reason for the adjustment [1] Group 1: Stock Performance - The company's American Depositary Receipts (ADR) experienced a significant drop of over 20% last Tuesday, marking the largest intraday decline since 1987 [1] Group 2: Legal Actions - A group of shareholders filed a proposed class-action lawsuit in federal court in New Jersey on July 28, seeking damages for alleged securities fraud occurring between May 7 and July 28, 2025 [1] - The plaintiffs accuse Novo Nordisk of making overly optimistic statements and disseminating false and misleading information, exaggerating its growth potential while concealing significant adverse facts [1] - The lawsuit claims that the stock price collapse resulting from the lowered performance guidance led to substantial losses for shareholders [1]